In our February/March issue:
PEER-REVIEWED ARTICLES
Measuring Patient Centricity in 3 Steps
Michael J. Howley, PhD, Peter Malamis
Though patient-centric design has become a popular “go-to” strategy to help transform clinical trials, its threat as just another fad remains real. Authors present a three-step process that trial managers can use to scientifically and accurately measure the level of patient centricity in their studies.
|
Enrollment Barriers, Solutions
Elizabeth Mahon, Jamie Roberts, Pat Furlong, Gina Uhlenbrauck, Jonca Bull, MD
A staggering number of clinical trials still fail to meet their patient recruitment goals, which can derail even the most promising investigational drug program.
This article unveils findings from a comprehensive survey that drills down on the perceived barriers and challenges in enrolling subjects across the clinical research enterprise—with the goal of informing recommendations for improvement.
|
All In On Outcomes
Matthew Reaney, Stephen Raymond, PhD
In an era of “real-world evidence,” the use of frequent data collection on clinical outcomes is critical to understanding and prescribing medication optimally. Authors discuss why measuring clinically relevant response requires routine and regular collection of outcomes data, and how such data can be integral to supporting future research and healthcare tools.
|
Recruitment: The Investigator Impact
Megan Souder, Linda B. Piller, MD, Charles E. Ford, PhD, Debra Egan, Therese S. Geraci, Leslie A. Holland-Klemme, Gail T. Louis, Robert A. Pospisil
Data on the relationship between investigator characteristics and cardiovascular clinical trial patient recruitment are extremely limited in scientific literature. An analysis of the largest antihypertensive trial ever offers a useful model on investigator tendencies when recruiting patients, findings which could help sites strengthen enrollment.
|
NEWS
View From Washington: Jill Wechsler on FDA's push for electronic health records, more diversified patient populations in clinical research.
View From Brussels: Peter O'Donnell examines the incoherencies in Europe's drug-access arrangements—using one high-profile example.
Global Report: Philip Ward reports on EMA's new strategy to gauge the effectiveness of pharmacovigilance activities.
Data Analysis: Study reveals sharp reduction in market exclusivity periods for first-in-class treatment entrants.
|
CLINICAL TRIAL INSIGHTS
Knowledge-Sharing Hits & Misses
Ken Getz
Despite the wealth of data collected, many inefficiencies exist in the site-sponsor transfer of insights from clinical trials. |
CLOSING THOUGHT
Lessons From ‘Autocomplete’
Rahlyn Gossen
Search-engine data offers a window to the public consciousness around clinical trial research and participation. |
|
|
If you would like to submit an article to Applied Clinical Trials, contact Lisa Henderson, Editorial Director - [email protected]
Applied Clinical Trials is free to qualified subscribers. To subscribe, click here.
Click here to contact the Applied Clinical Trials sales team. |
